BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23017810)

  • 1. Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone.
    Künzel HE; Apostolopoulou K; Pallauf A; Gerum S; Merkle K; Schulz S; Fischer E; Brand V; Bidlingmaier M; Endres S; Beuschlein F; Reincke M
    J Psychiatr Res; 2012 Dec; 46(12):1650-4. PubMed ID: 23017810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically.
    Ahmed AH; Gordon RD; Sukor N; Pimenta E; Stowasser M
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2904-11. PubMed ID: 21778218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: a cohort study.
    Köhler A; Sarkis AL; Heinrich DA; Müller L; Handgriff L; Deniz S; Schneider H; Künzel H; Ladurner R; Reincke M; Adolf C
    Eur J Endocrinol; 2021 Oct; 185(5):663-672. PubMed ID: 34468397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism.
    Sukor N; Kogovsek C; Gordon RD; Robson D; Stowasser M
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1360-4. PubMed ID: 20089615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: a cross-sectional study.
    Apostolopoulou K; Künzel HE; Gerum S; Merkle K; Schulz S; Fischer E; Pallauf A; Brand V; Bidlingmaier M; Endres S; Beuschlein F; Reincke M
    World J Biol Psychiatry; 2014 Jan; 15(1):26-35. PubMed ID: 22568586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Worsening of lipid metabolism after successful treatment of primary aldosteronism.
    Adolf C; Asbach E; Dietz AS; Lang K; Hahner S; Quinkler M; Rump LC; Bidlingmaier M; Treitl M; Ladurner R; Beuschlein F; Reincke M
    Endocrine; 2016 Oct; 54(1):198-205. PubMed ID: 27179655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-saline infusion test aldosterone levels indicate severity and outcome in primary aldosteronism.
    Weigel M; Riester A; Hanslik G; Lang K; Willenberg HS; Endres S; Allolio B; Beuschlein F; Reincke M; Quinkler M
    Eur J Endocrinol; 2015 Apr; 172(4):443-50. PubMed ID: 25630564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism.
    Katabami T; Fukuda H; Tsukiyama H; Tanaka Y; Takeda Y; Kurihara I; Ito H; Tsuiki M; Ichijo T; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Sone M; Inagaki N; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Yamamoto K; Ogo A; Yanase T; Suzuki T; Naruse M;
    J Hypertens; 2019 Jul; 37(7):1513-1520. PubMed ID: 31145370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment.
    Velema M; Dekkers T; Hermus A; Timmers H; Lenders J; Groenewoud H; Schultze Kool L; Langenhuijsen J; Prejbisz A; van der Wilt GJ; Deinum J;
    J Clin Endocrinol Metab; 2018 Jan; 103(1):16-24. PubMed ID: 29099925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous remission of idiopathic aldosteronism after long-term treatment with spironolactone: results from the German Conn's Registry.
    Fischer E; Beuschlein F; Degenhart C; Jung P; Bidlingmaier M; Reincke M
    Clin Endocrinol (Oxf); 2012 Apr; 76(4):473-7. PubMed ID: 21958049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of reduced mineralocorticoid receptor activation by unilateral adrenalectomy vs mineralocorticoid antagonist treatment in patients with primary aldosteronism - Implications for depression and anxiety.
    Murck H; Adolf C; Schneider A; Schlageter L; Heinrich D; Ritzel K; Sturm L; Quinkler M; Beuschlein F; Reincke M; Künzel H
    J Psychiatr Res; 2021 May; 137():376-382. PubMed ID: 33761426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assay characteristics influence the aldosterone to renin ratio as a screening tool for primary aldosteronism: results of the German Conn's registry.
    Fischer E; Reuschl S; Quinkler M; Rump LC; Hahner S; Bidlingmaier M; Reincke M;
    Horm Metab Res; 2013 Jul; 45(7):526-31. PubMed ID: 23613013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism.
    Lin YF; Peng KY; Chang CH; Hu YH; Wu VC; Chung SD;
    Endocrinol Metab (Seoul); 2020 Dec; 35(4):838-846. PubMed ID: 33261310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.
    Yoneda T; Demura M; Takata H; Kometani M; Karashima S; Yamagishi M; Takeda Y
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1109-13. PubMed ID: 22337911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of aldosterone and renin concentrations with inflammation-the Study of Health in Pomerania and the German Conn's Registry.
    Grotevendt A; Wallaschofski H; Reincke M; Adolf C; Quinkler M; Nauck M; Hoffmann W; Rettig R; Hannemann A
    Endocrine; 2017 Aug; 57(2):298-307. PubMed ID: 28638984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness.
    Holaj R; Rosa J; Zelinka T; Štrauch B; Petrák O; Indra T; Šomlóová Z; Michalský D; Novák K; Wichterle D; Widimský J
    J Hypertens; 2015 Apr; 33(4):874-82; discussion 882. PubMed ID: 25490707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of primary aldosteronism treatment on patients with primary aldosteronism and chronic kidney disease.
    Nakano Y; Murakami M; Hara K; Fukuda T; Horino M; Takeuchi A; Niitsu Y; Shiba K; Tsujimoto K; Komiya C; Yokoyama M; Ikeda K; Yoshimoto T; Fujii Y; Yamada T
    Clin Endocrinol (Oxf); 2023 Mar; 98(3):323-331. PubMed ID: 36367014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metabolic Outcomes of Primary Aldosteronism Patients Receiving Adrenalectomy or Spironolactone Treatments].
    Xu C; Chen T; Mo D; Zhang T; Zhou F; Tian H; Ren Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1227-1232. PubMed ID: 38162054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
    Riester A; Reincke M
    Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas.
    Rossi E; Sani C; Perazzoli F; Casoli MC; Negro A; Dotti C
    Am J Hypertens; 1995 Sep; 8(9):884-93. PubMed ID: 8541003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.